Shares in AVI BioPharma more than doubled Wednesday on the announcement it had received one patent and a notice of allowance on another, both dealing with certain agents that modulate stem cell maturation. One analyst said the news the company was moving into the stem cell area contributed to its share price rise because stem cells are "hot right now," but said he expected enthusiasm over the development to decline because it is too early to know if the technology will yield anything.

Related Summaries